Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 21 and up

Digital harm reduction treatment for alcohol use disorder

Official title: eHaRT-A: Adapting an Evidence-based, In-person Harm Reduction Treatment Into a Virtual Care Telehealth Intervention for People With Lived Experience of Homelessness and Alcohol Use Disorder

Run by University of Washington · NCT06702007 · Data updated 2026-11-12

This study is testing a new online treatment for alcohol use disorder to see if it helps people who have been homeless and are now in supportive housing feel better and reduce alcohol-related problems compared to regular services.

Quick facts

PhasePhase 3
Study typeInterventional
Ages21 Years and up
SexAll
Enrollment160 (estimated)
SponsorUniversity of Washington
Academic / other
Locations1 site (Seattle, Washington)
StatusRecruiting
StartedJanuary 20, 2025
Main results expectedJanuary 2027
Study endsAugust 31, 2027
Registry record updatedJuly 8, 2025
Trial IDNCT06702007 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals aged 21 and older who are currently registered clients at Housing First sites and have a recent history of alcohol use.

Probably not a fit

Patients who are not currently drinking or those who pose a risk to the safety of others may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to convert a successful in-person harm-reduction treatment for alcohol use disorder into a digital format called eHaRT-A. It is specifically designed for individuals who have experienced homelessness and are currently living in permanent supportive housing. The study will assess whether eHaRT-A is more effective than standard Housing First services in reducing alcohol-related harm and enhancing participants' quality of life. Participants will engage with the digital platform to receive tailored support and interventions.

Why it matters

Potential benefit: If successful, this approach could significantly reduce alcohol-related harm and improve the quality of life for individuals with alcohol use disorder who have experienced homelessness.

How similar studies have gone: Other studies have shown promise in using digital platforms for harm reduction, but this specific approach targeting the homeless population with alcohol use disorder is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Being at least 21 years of age
* Speak English fluently
* Currently a registered client at one of the Housing First sites
* Currently drinking (has used alcohol in the past 2 weeks)
* Meeting criteria for "current" (e.g., past-year) AUD according to the Diagnostic and Statistical Manual of Mental Health Disorders, Fifth Edition (determined as scoring \>= 2 on the SCID-5-CV)

Exclusion Criteria:

* Enrollment in any related treatment studies (including studies by this research team)
* Refusal or inability to consent
* Constituting a risk to the safety and security of residents or staff

Where it's running

  • Downtown Emergency Service Center
    Seattle, Washington, United States
    Recruiting

Study contacts

  • Principal investigator: Tessa Frohe, PhD — University of Washington
  • Study coordinator: Emily Taylor
  • Email: emt07@uw.edu
  • Phone: 206-744-1873

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.